참고문헌
- Altundag K, Aksoy S, Gullu I, et al (2004). Salvage ifosfamidedoxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with Cisplatin-based chemotherapy. Med Oncol, 21, 211-5. https://doi.org/10.1385/MO:21:3:211
- Au E, Ang PT (1994). A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol, 5, 87-9. https://doi.org/10.1093/annonc/5.suppl_3.S87
- Azli N, Fandi A, Bachouchi M, et al (1995). Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J Sci Am, 1, 222-9.
- Boussen H, Cvitkovic E, Wendling JL, et al (1991). Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil. J Clin Oncol, 9, 1675-81. https://doi.org/10.1200/JCO.1991.9.9.1675
- Chan AT, Grégoire V, Lefebvre JL, et al (2010). Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 187-9. https://doi.org/10.1093/annonc/mdp494
- Chan ATC, Ma B, Tung S, et al (2007). Biweekly gemcitabine and oxaliplatin (GEMOX) in first-line metastatic or recurrent nasopharyngeal carcinoma (NPC) an early report. J Clin Oncol Proc Am Soc Clin Oncol, 25, 6071.
- Chua DT, Kwong DLW, Sham JS, et al (2000). A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur J Cancer, 36, 736-41. https://doi.org/10.1016/S0959-8049(00)00008-3
- Chua DT, Sham JS, Au GK, et al (2003). A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol, 39, 361-6. https://doi.org/10.1016/S1368-8375(02)00120-3
- Chua DT, Sham JS, Au GK, et al (2005). A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol, 41, 589-95. https://doi.org/10.1016/j.oraloncology.2005.01.008
- Fong KW, Chua EJ, Chua ET, et al (1996). Patient profile and survival in 270 computer tomography-staged patients with nasopharyngeal cancer treated at the Singapore general hospital. Ann Acad Med Singapore, 25, 341-6.
- Foo KF, Tan EH, Leong SS, et al (2002). Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol, 13, 150-6. https://doi.org/10.1093/annonc/mdf002
- Guo Y, Glisson BS (2010). Systemic treatment for incurable recurrent and/or metastatic nasopharyngeal carcinoma. In 'Nasopharyngeal cancer multidisciplinary management. Eds Lu JJ, Cooper JS and Lee AWM. Springer -Verlag Berlin Heidelberg, pp 267-75.
- Hasbini A, Mahjoubi R, Fandi A, et al (1999). Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann Oncol, 10, 421-5. https://doi.org/10.1023/A:1008342828496
- Huang HQ, Zhou ZM, Li YH, et al (2002). Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma. Ai Zheng, 21, 409-11.
- Leong SS, Wee J, Tay MH (2005). Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a phase II trial using a triplet combination. Cancer, 103, 569-75. https://doi.org/10.1002/cncr.20804
- Ma BB, Hui EP, Chan AT, et al (2008). Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci, 99, 1311-8. https://doi.org/10.1111/j.1349-7006.2008.00836.x
- Ma BB, Tannock IF, Pond GR et al (2002). Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer, 95, 2516-23. https://doi.org/10.1002/cncr.10995
- McCarthy JS, Tannock IF, Degendorfer P, et al (2002). A phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol, 38, 686-90. https://doi.org/10.1016/S1368-8375(01)00134-8
- Ngan RK, Yiu HH, Lau WH, et al (2002). Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol, 13, 1252-8. https://doi.org/10.1093/annonc/mdf200
- Onat H, Basaran M, Esassolak, et al (2002). High-dose epirubicin and cisplatin in locally advanced undifferentiated nasopharyngeal carcinoma. Clin Oncol, 14, 449-54. https://doi.org/10.1053/clon.2002.0110
- Perez CA, Devineni VR, Marcial-Vega V, et al(1992). Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys, 23, 271-80. https://doi.org/10.1016/0360-3016(92)90741-Y
- Razak AR, Siu LL, Liu FF et al (2010). Nasopharyngeal carcinoma: the next challenges. Eur J Cancer, 46, 1967-78. https://doi.org/10.1016/j.ejca.2010.04.004
- Siu LL, Czaykowski PM, Tannock IF, et al (1998). Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J Clin Oncol, 16, 2514-21. https://doi.org/10.1200/JCO.1998.16.7.2514
- Taamma A, Fandi A, Azli N, et al (1999). Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer, 86, 1101-8. https://doi.org/10.1002/(SICI)1097-0142(19991001)86:7<1101::AID-CNCR2>3.0.CO;2-R
- Wang J, Li J, Hong X, et al (2008). Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma. Oral Oncol, 44, 464-70. https://doi.org/10.1016/j.oraloncology.2007.06.004
- Wei KR, Yu YL, Yang YY, et al (2010). Epidemiological trendsof nasopharyngeal carcinoma in China. Asian Pac J Cancer Prev, 11, 29-32.
- Wei K, Xu Y, Liu J, et al (2010). No incidence trends and no change inpathological proportions of nasopharyngeal carcinoma in Zhongshan in 1970-2007. Asian Pac J Cancer Prev, 11,1595-9.
- Yeo W, Leung TW, Chan AT, et al (1998). A phase II study combination of paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer, 34, 2027-31. https://doi.org/10.1016/S0959-8049(98)00280-9
피인용 문헌
- Biomarkers for monitoring chemotherapy-induced cardiotoxicity vol.54, pp.2, 2017, https://doi.org/10.1080/10408363.2016.1261270